EUCTR2016-002503-26-ES进行中（未招募）1 期
Phase Ib/II trial to evaluate safety and efficacy of oral ixazomib in combination with sirolimus and tacrolimus in the prophylaxis of chronic graft-versus-host disease
Fundación Pública Andaluza para la Gestión en Salud de Sevilla (FISEVI)0 个研究点目标入组 152 人开始时间: 2017年1月4日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 152
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Male or female patients 18 years or older.
- •2.Patients having received reduced intensity conditioning (RIC) peripheral blood allogeneic stem cell transplantation.
- •3.Patients undergoing hematopoietic stem cell transplant from a matched or a single mismatched related or unrelated donor as definition accepted by protocol.
- •4.Patients receiving GVHD prophylaxis with sirolimus and tacrolimus and on stable levels during the last 2 weeks before inclusion.
- •5.Voluntary written consent must be given before performance of any study related procedure.
- •6.Female patients who accomplish with requisitions for not possibility of pregnancy (menopausia, effective methods of contraception), as detailed by protocol.
- •7.Eastern Cooperative Oncology Group (ECOG) performance status and/or other performance status 0, 1, or 2.
- •8.Patients must meet the following clinical laboratory criteria:
- •Absolute neutrophil count (ANC) 1,000/mm3 and platelet count 75,000/mm3. Platelet transfusions to help patients meet eligibility criteria are not allowed within 3 days before study enrollment.
- •Total bilirubin 1.5 the upper limit of the normal range (ULN).
- •Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 3 ULN.
- •Calculated creatinine clearance 30 mL/min (see Section 11.2).
- •9.Ability to swallow and tolerate oral medication.
- •10.Absence of gastrointestinal symptoms that precludes oral intake and absorption.
- •11.Off antibiotics and amphotericin B formulations, voriconazole or other anti-fungal therapy for the treatment of active proven, probable or possible infections.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 124
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 30
排除标准
- •1.Female patients who are lactating or have a positive serum pregnancy test during the screening period.
- •2.Major surgery within 14 days before enrollment.
- •3.Central nervous system involvement with malignant cells.
- •4.Uncontrolled infection within 14 days before study enrollment.
- •5.Evidence of current uncontrolled cardiovascular conditions, including uncontrolled hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure, unstable angina, or myocardial infarction within the past 6 months.
- •6.Systemic treatment, within 14 days before the first dose of ixazomib, with strong CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital), or use of Ginkgo biloba or St. John’s wort.
- •7.Ongoing or active systemic infection, active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive.
- •8.Any serious medical or psychiatric illness that could, in the investigator’s opinion, potentially interfere with the completion of treatment according to this protocol.
- •9.Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent.
- •10.Diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease. Patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.
- •11.Patient has Grade 1 peripheral neuropathy.
- •12.Participation in other clinical trials, including those with other investigational agents not included in this trial, within 30 days of the start of this trial and throughout the duration of this trial.
- •13. Patients that have previously been treated with ixazomib, or participated in a study with ixazomib whether treated with ixazomib or not.
- •14.Active Graft versus host disease at the time of inclusion: patients are allowed to be included if acute GVHD is in complete remission and are receiving systemic steroids at < 0.25 mg / kg.
- •15.Active hematologic malignancy at the time of inclusion.
- •16.Active microangiopathy at the time of inclusion (according to IWG criteria)
- •17. Gastrointestinal disease or procedure than can interfere with oral absortion , intolerance to the ixazomib or difficulty to swallow.
研究者
相似试验
招募中
2 期
Trial evaluating the safety and efficacy of Venetoclax in addition to a standard conditioning regime in patients with certain forms of leukemia undergoing allogeneic blood stem cell transplantation2024-514688-24-00Heinrich-Heine-Universitaet Duesseldorf38
招募中
1 期
Trial evaluating the safety and efficacy of Venetoclax in addition to a standard conditioning regime in patients with certain forms of leukemia undergoing allogeneic blood stem cell transplantatioCTIS2024-514688-24-00Heinrich-Heine-Universitaet Duesseldorf38
进行中（未招募）
不适用
Phase II trial evaluating the efficacy and safety of physician chosen chemotherapy with hormonal therapy in patients with heavily pretreated advanced ovarian cancer: A multicenter pilot studyNeoplasmsKCT0004571Inha University Hospital58
已完成
2 期
A phase II trial evaluating the safety and efficacy of the addition of concurrent anti-PD-1 nivolumab to standard first-line chemotherapy and radiotherapy in locally advanced stage IIIA/B Non-Small Cell Lung Carcinomalocally advanced non-small cell lung cancer1003866610029107NL-OMON44704European Thoracic Oncology Platform (ETOP)18
进行中（未招募）
1 期
Trial to evaluate how severe the side effects are and how well the addition of Nivolumab to standard treatment works in patients with advanced NSCLC.locally advanced stage IIIA/B NSCLCMedDRA version: 20.0Level: PTClassification code 10029520Term: Non-small cell lung cancer stage IIIASystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10029521Term: Non-small cell lung cancer stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-005097-11-BEETOP (European Thoracic Oncology Platform)78